Hematologic malignancies are cancers affecting the blood and lymph systems. The disease begins in the cells of the immune system or in blood-forming tissue cells, such as bone marrow. The cancer can be treated with different therapies like radiotherapy, stem cell transplantation, chemotherapy, and immunotherapy.
Innovative Drugs to Treat Different Types of Cancers
Hematologic malignancies are categorized into lymphoma, multiple myeloma, and leukemia. Leukemia is further classified into chronic lymphocytic, acute lymphocytic, chronic myeloid leukemia, and acute myeloid. Leukemia was the leading segment in 2016 due to popular brands like Imbruvica, Glivec, and Rituxan, which are reported to be some of the main revenue-generating oncology drugs. Acute lymphocytic leukemia is the most communally occurring type of leukemia.
Major companies in this field are focusing on R&D to introduce novel products and technologies. For instance, Pfizer, Servier, and Cellectis recently presented initial results of two phase 1 trials for UCART19, the allogeneic anti-CD19 CAR T-cell product by Pfizer and Servier, at the European society for Blood and Marrow Transplantation (EBMT) Annual Meeting. Acute myeloid leukemia segment is likely to witness the fastest growth during the forecast period. on account of the presence of a strong product pipeline and their expected commercialization.
Market Overview
According to Grand View Research, Inc., the worldwide hematologic malignancies market is predicted to achieve USD 85.8 billion by 2025. Factors such as increasing alliances between various government organizations and research institutes for developing innovative therapies would drive the market. Moreover, positive government support along with the rising awareness among patients and healthcare authorities can also propel the market expansion in the coming years.
Geographically, Asia Pacific is expected to be the fastest-growing market with a CAGR of 12.5% due to availability of effective treatments and growing investments for the development of healthcare infrastructure. Some of the leading companies operating in the market include GlaxoSmithKline PLC; Pfizer, Inc.; Johnson & Johnson Services, Inc.; Hoffmann-LA Roche Ltd.; and Bristol-Myers Squibb Company.
In-Depth Research Report On Hematologic Malignancies Market:
https://www.grandviewresearch.com/industry-analysis/hematologic-malignancies-market
No comments:
Post a Comment